vs
爱德华生命科学（EW）与赛莱默（XYL）财务数据对比。点击上方公司名可切换其他公司
赛莱默的季度营收约是爱德华生命科学的1.3倍（$2.1B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 8.9%，领先14.2%），爱德华生命科学同比增速更快（16.7% vs 2.7%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -1.0%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
该文本为植物学对木质部的定义说明，并非赛莱默公司（Xylem Inc.）的企业业务介绍。Xylem Inc.是一家专注于水技术与解决方案的全球企业，提供水务基础设施、水环境治理等相关设备与服务。
EW vs XYL — 直观对比
营收规模更大
XYL
是对方的1.3倍
$1.6B
营收增速更快
EW
高出14.0%
2.7%
净利率更高
EW
高出14.2%
8.9%
两年增速更快
EW
近两年复合增速
-1.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $2.1B |
| 净利润 | $380.7M | $189.0M |
| 毛利率 | 78.0% | 37.8% |
| 营业利润率 | 1.8% | 11.5% |
| 净利率 | 23.1% | 8.9% |
| 营收同比 | 16.7% | 2.7% |
| 净利润同比 | 6.8% | 13.2% |
| 每股收益（稀释后） | $0.66 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWXYL
| Q1 26 | $1.6B | $2.1B | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.6B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.4B | $2.1B | ||
| Q2 24 | $1.4B | $2.2B |
净利润EWXYL
| Q1 26 | $380.7M | $189.0M | ||
| Q4 25 | $91.2M | $335.0M | ||
| Q3 25 | $291.1M | $227.0M | ||
| Q2 25 | $333.2M | $226.0M | ||
| Q1 25 | $358.0M | $169.0M | ||
| Q4 24 | $385.6M | $326.0M | ||
| Q3 24 | $3.1B | $217.0M | ||
| Q2 24 | $366.3M | $194.0M |
毛利率EWXYL
| Q1 26 | 78.0% | 37.8% | ||
| Q4 25 | 78.1% | 38.9% | ||
| Q3 25 | 77.8% | 38.9% | ||
| Q2 25 | 77.5% | 38.8% | ||
| Q1 25 | 78.7% | 37.1% | ||
| Q4 24 | 78.9% | 38.0% | ||
| Q3 24 | 80.6% | 37.3% | ||
| Q2 24 | 79.9% | 37.8% |
营业利润率EWXYL
| Q1 26 | 1.8% | 11.5% | ||
| Q4 25 | 9.6% | 14.7% | ||
| Q3 25 | 19.8% | 14.7% | ||
| Q2 25 | 26.8% | 13.3% | ||
| Q1 25 | 27.9% | 11.2% | ||
| Q4 24 | 22.6% | 11.8% | ||
| Q3 24 | 25.9% | 13.3% | ||
| Q2 24 | 26.8% | 11.7% |
净利率EWXYL
| Q1 26 | 23.1% | 8.9% | ||
| Q4 25 | 5.8% | 14.0% | ||
| Q3 25 | 18.7% | 10.0% | ||
| Q2 25 | 21.7% | 9.8% | ||
| Q1 25 | 25.3% | 8.2% | ||
| Q4 24 | 27.8% | 14.5% | ||
| Q3 24 | 226.7% | 10.3% | ||
| Q2 24 | 26.7% | 8.9% |
每股收益（稀释后）EWXYL
| Q1 26 | $0.66 | $0.79 | ||
| Q4 25 | $0.16 | $1.37 | ||
| Q3 25 | $0.50 | $0.93 | ||
| Q2 25 | $0.56 | $0.93 | ||
| Q1 25 | $0.61 | $0.69 | ||
| Q4 24 | $0.65 | $1.33 | ||
| Q3 24 | $5.13 | $0.89 | ||
| Q2 24 | $0.61 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $808.0M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | — | $11.0B |
| 总资产 | — | $17.0B |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资EWXYL
| Q1 26 | — | $808.0M | ||
| Q4 25 | $4.2B | $1.5B | ||
| Q3 25 | $3.8B | $1.2B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $3.9B | $1.1B | ||
| Q4 24 | $4.0B | $1.1B | ||
| Q3 24 | $4.4B | $989.0M | ||
| Q2 24 | $2.0B | $815.0M |
总债务EWXYL
| Q1 26 | — | $1.9B | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EWXYL
| Q1 26 | — | $11.0B | ||
| Q4 25 | $10.3B | $11.5B | ||
| Q3 25 | $10.2B | $11.2B | ||
| Q2 25 | $10.5B | $11.1B | ||
| Q1 25 | $10.1B | $10.8B | ||
| Q4 24 | $10.0B | $10.6B | ||
| Q3 24 | $9.5B | $10.6B | ||
| Q2 24 | $7.4B | $10.3B |
总资产EWXYL
| Q1 26 | — | $17.0B | ||
| Q4 25 | $13.7B | $17.6B | ||
| Q3 25 | $13.3B | $17.3B | ||
| Q2 25 | $13.5B | $17.2B | ||
| Q1 25 | $13.0B | $16.6B | ||
| Q4 24 | $13.1B | $16.5B | ||
| Q3 24 | $13.0B | $16.0B | ||
| Q2 24 | $10.1B | $15.8B |
负债/权益比EWXYL
| Q1 26 | — | 0.18× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
XYL
| Revenue from products | $1.8B | 83% |
| Revenue from services | $368.0M | 17% |
